Myung-Ju Ahn

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Myung-Ju Ahn
May 1, 2025, 17:14 | Drugs
Ana Velázquez Mañana highlights NEJM study by John Heymach on Zongertinib’s efficacy in HER2-Mutant NSCLC at AACR25
Ana Velázquez Mañana, shared a post on X, about a recent article by John Heymach et…
May 1, 2025, 16:11 | Science
David Planchard Highlights Promise and Access Challenges of HER2-TKIs for HER2-Mutant NSCLC
David Planchard, Thoracic Oncologist, Professor at University Paris Saclay and Head of Thoracic Cancer Group…
Apr 29, 2025, 13:57 | Insight
Rami Manochakian: Zongertinib in Previously Treated HER2-Mutant NSCLC
Rami Manochakian, Vice President of the North American Neuroendocrine Tumor Society, shared an article on…
Mar 18, 2025, 08:51 | Blog
Matt Hellmann: The detection of MRD by assaying ctDNA in patients with cancer
Matt Hellmann, Vice President of Early Oncology Development at AstraZeneca, shared an article Roy S.…
Feb 6, 2025, 15:29 | Blog
Antonio Calles: Cardiotoxicity of osimertinib is real
Antonio Calles, Head of the Lung Cancer Unit at Hospital Ruber Internacional, shared an article…
Jan 12, 2025, 13:43 | Science
Dipesh Uprety: TROPION-Lung05 - a phase II trial on NSCLC by Jacob Sands et al.
Dipesh Uprety, Assistant Professor of Thoracic Oncology at Karmanos Cancer Institute, shared a post on X…
Jan 10, 2025, 17:01 | Insight
Biagio Ricciuti: Datopotamab Deruxtecan in Advanced/Metastatic NSCLC by Jacob Sands et al.
Biagio Ricciuti, Thoracic Medical Oncologist at the Dana-Farber Cancer Institute, shared a post on X about…
Jan 10, 2025, 05:59 | Insight
Results From the Phase II TROPION-Lung05 Study by Jacob Sands et al.
A recent paper by Jacob Sands, Medical Oncologist at Dana-Farber Cancer Institute, was mentioned by…
Jan 8, 2025, 14:07 | Science
Rami Manochakian: Results of TROPION/Lung05 Phase 2 trial are out
Rami Manochakian shared a post on X: "Hot off the press. Just published in the Journal…
Dec 19, 2024, 11:54 | Opinion
Lung Cancer Trial Highlights from 2024 By Yakup Ergün
Yakup Ergün, Medical Oncologist at Antalya City Hospital, posted on X: “What happened in Lung…
Nov 18, 2024, 17:34 | Blog
Evaluating the clinical value of a tumor-naïve, methylation-based cell-free DNA assay in resected NSCLC - IASLC
IASLC posted on X about recent paper by Tae Hee Hong et al., titled "Clinical…
Nov 3, 2024, 13:55 | Insight
Highlights from JLCS24 by Stephen Liu
The 65th Annual Meeting of the Japanese Lung Cancer Society was held at PACIFICO Yokohama…
Oct 20, 2024, 11:34 | Insight
5 papers about lung cancer suggested by Stephen Liu
Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a few…
Oct 13, 2024, 07:07 | Blog
Stephen V Liu: Cardiotoxicity of osimertinib in real world population with EGFR NSCLC
Stephen V Liu shared on X: "Cardiotoxicity of osimertinib in real world population with EGFR…
Sep 26, 2024, 15:35 | Blog
Jarushka Naidoo: TL01 Phase III Datopotamab-Deruxtecan vs Docetaxel in second-line NSCLC
Jarushka Naidoo shared a post on X, about recent paper published in Journal of Clinical…
Sep 18, 2024, 23:22 | Insight
Stephen Liu: Update from TROPION-Lung01
Stephen Liu shared a post on X: “Update from TROPION-Lung01 presented at WCLC24 and now Journal…
Sep 12, 2024, 09:48 | Insight
Datopotamab deruxtecan vs docetaxel for previously treated advanced NSCLC
Erman Akkus shared a post on X about a recent paper by Myung-Ju Ahn et…
Sep 10, 2024, 14:57 | Insight
Article of the day, September 10th, suggested by the Immune Oncology Research Institute
Immune Oncology Research Institute shared a post on LinkedIn: “Article of the day! Suggest by the Immune…
Aug 7, 2024, 16:50 | Blog
The recipients of the 2024 ESMO Society Awards
The 2024 ESMO Society Awards have been announced on 6th August by ESMO. ESMO recently…
Jul 12, 2024, 23:29 | Insight
Clinical Utility of Pre-surgical ctDNA Detection in Early Stage NSCLC
Biagio Ricciuti shared on X: "Clinical Utility of Pre-surgical ctDNA Detection in Early Stage NSCLC…
Jun 26, 2024, 12:05 | Insight
Piotr Wysocki: Osimertinib after radiochemotherapy improves PFS in EGFR-mutated NSCLC patients – but is it really what they need?
Piotr Wysocki recently posted on LinkedIn: "The results of the LAURA study were presented during a…
Jun 10, 2024, 00:53 | Insight
Vijith Shetty: Osimertinib Could Alter SOC for Stage III EGFR+ NSCLC
Vijith Shetty, Associate Professor and Consultant Medical Oncologist at KS Hegde Medical Academy, shared on…
All: 22 Posts: 1 - 100
Special Coverage